Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex - Wikidata - wikimedia - TriplyDB

Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex

Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex

http://www.wikidata.org/entity/Q38818673

about

Targeting the latent reservoir to achieve functional HIV cure Editing the Neuronal Genome: a CRISPR View of Chromatin Regulation in Neuronal Development, Function, and Plasticity Achieving HIV-1 Control through RNA-Directed Gene Regulation Antiretroviral therapy: Shifting sands Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors.Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems.Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape.Specific Reactivation of Latent HIV-1 by dCas9-SunTag-VP64-mediated Guide RNA Targeting the HIV-1 Promoter.Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense.Gene Editing for Treatment of Neurological Infections.The variances of Sp1 and NF-κB elements correlate with the greater capacity of Chinese HIV-1 B'-LTR for driving gene expression.Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS.CRISPR-Cas9 technology and its application in haematological disorders.Stem cell-based therapies for HIV/AIDS.A CRISPR Approach for Reactivating Latent HIV-1.CRISPR/Cas9: a double-edged sword when used to combat HIV infection.Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants.Targeting TRIM5α in HIV Cure Strategies for the CRISPR-Cas9 Era.Cell and Gene Therapy for HIV Cure.Genome editing technologies to fight infectious diseases.CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy.Bone marrow stem cells to destroy circulating HIV: a hypothetical therapeutic strategy.Ultrasound-targeted microbubble destruction-mediated Foxp3 knockdown may suppress the tumor growth of HCC mice by relieving immunosuppressive Tregs function.Epigenetic editing: How cutting-edge targeted epigenetic modification might provide novel avenues for autoimmune disease therapy.Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies.Stable Transcriptional Repression and Parasitism of HIV-1.Comprehensive off-target analysis of dCas9-SAM-mediated HIV reactivation via long noncoding RNA and mRNA profiling

P2860

Q26745923-F1EC0CCF-57D5-4D6C-938D-86C2672DDB86 Q28075883-BEC06593-5073-4C50-B8BE-563B52CCD91E Q28080090-CDF5B933-0759-4D6C-91B4-42334EA96849 Q30384683-9A5037FE-F319-4AC4-ACA7-D8C1EBA8EEA4 Q35942658-995FDE1B-1363-43E9-859D-6E891B0D93A6 Q36060923-44F8D3A4-0237-489B-9F70-E8DD7E639FB0 Q36216276-159B4303-3EAB-430E-9E90-A26593DADAD0 Q36675349-2B9CD0C1-A357-4C09-9CAF-566FDCFE883C Q36730743-30963A32-F6C5-4E69-83B8-DF625630089B Q37136471-DFACADA0-77A4-4C66-BC12-ECF714348D10 Q37307353-013E12D4-F6DB-444E-A267-B0AFC4A73DEF Q38687781-82E4A129-3F96-4CA0-A03B-91F3F4A24D19 Q38822073-B5EBA15D-8388-4F61-9D0C-F82F4FB6E327 Q38827119-26A587C3-4271-4948-8BCB-A68F2F950BA4 Q38919964-4CAB1511-4845-4CE2-ABEF-B27DB28F8936 Q40657354-A946B9A4-A253-4DB3-B26E-2526E704A532 Q43212335-96F08C3D-0186-430E-85C4-8A1CA50D85A3 Q45875539-F7C06DDD-8C8C-405F-A71A-BCEDE29424F6 Q47236016-049188BE-CF27-40AF-8B0E-DBEE89ECE8FD Q47392998-328E842D-1909-4455-A477-86FE5C928F07 Q47553089-5ACAE506-82E0-4BAC-9A4D-2BA68703F8C1 Q49462231-F4CBF99C-C88C-4B93-8C15-C8CF230B9E4A Q49882362-75D6A38F-F0CE-4EA2-8519-7BDD60308204 Q50111348-3306052B-92C1-4011-BCB9-CEE49F4E5E4B Q52431127-D9C8E5B6-E57B-4BF4-9AF5-278CC3305780 Q55399452-87C57918-85A4-4A6F-8036-A3CCB75C7C7F Q58755636-3AB08718-307E-452D-BE0F-EFFE8CB48198

P2860

Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex

http://www.wikidata.org/entity/Q38818673

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex

@en

type

label

Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex

@en

prefLabel

Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex

@en

P1433

Q38818673-9B383697-26B5-428D-8423-0EB72DBD3B77

P1476

Q38818673-D593FA6E-FAFC-4F50-85DE-0445048F6F60

P2093

Q38818673-2E5F163C-F00C-425A-BD6E-2F73472636DF

Q38818673-47B6F21F-8CC0-4C6E-BA52-695C63150853

Q38818673-759CF2DA-E0EE-4EB8-9E4E-3EE8BD997C81

Q38818673-8F67B023-A911-43F7-B018-7254C3453955

Q38818673-A2677D01-0447-4ED5-801B-68831A11DEDD

Q38818673-CD88CA19-B568-4665-A2A4-F7CECD3402D6

P2860

Q38818673-00F4FDE2-E0A4-44AF-8C68-C00641C1A939

Q38818673-01D3C0C4-8D09-4A37-B3AE-89BA7EA8C731

Q38818673-07D7A515-1753-4745-95CE-557007FC2847

Q38818673-1619A693-517C-4E33-A638-FF0E46069E09

Q38818673-16294156-85F6-409A-9C77-632DD065C98E

Q38818673-1634CAE7-E318-4E60-89B5-42951840B1C7

Q38818673-191E0849-D525-4790-A14A-980E546D2F2D

Q38818673-1C37C49B-44E8-4785-A8DD-25F5366235D0

Q38818673-211A0424-502D-46D0-BC1F-61E553A3F7DF

Q38818673-2489C8F1-EDFE-4A8F-8C92-8BF22ED026FE

P304

Q38818673-17D713FE-E2E2-41F0-A4AF-0493C8DB5C2D

P31

Q38818673-07D59576-C867-46CA-BACF-5B0F2D3BF8E7

P356

Q38818673-6A2E73C4-0B46-4C04-A541-DE0922243275

P433

Q38818673-528304D7-7E65-4EC2-A691-1608FECFA278

P478

Q38818673-6080F210-5A37-413F-A1FD-67148AA47461

P50

Q38818673-13946BC0-5ED8-40E1-85EE-823BFAB84CD1

Q38818673-4CCD0A4E-FDDA-4C3D-AA98-738DBF29E935

Q38818673-D6A660B3-43CB-459F-B6A6-267C68A2304A

P577

Q38818673-15BD0F80-5895-4E89-96B0-02D788864241

P5875

Q38818673-9B4E690A-ED5A-4AD0-AADE-016E5F015078

P698

Q38818673-D0C5B94C-45A1-43B4-AE73-4A17BB3F7841

P921

Q38818673-B673F16A-F807-4457-91D5-84C15C796E12

P932

Q38818673-BEFA6D83-9C63-4679-A498-16ECB1A77477

P356

P1433

Molecular Therapy

P1476

Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex

@en

P2093

Daniel C Lazar

http://www.w3.org/2001/XMLSchema#string

Marc S Weinberg

http://www.w3.org/2001/XMLSchema#string

Mayumi Takahashi

http://www.w3.org/2001/XMLSchema#string

Sheena M Saayman

http://www.w3.org/2001/XMLSchema#string

Tristan A Scott

http://www.w3.org/2001/XMLSchema#string

Vicente Planelles

http://www.w3.org/2001/XMLSchema#string

P2860

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid

RNA-guided human genome engineering via Cas9

Multiplex genome engineering using CRISPR/Cas systems

CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes

Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells

Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity

Emerging strategies to deplete the HIV reservoir

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

RNA-programmed genome editing in human cells

Genome editing. The new frontier of genome engineering with CRISPR-Cas9

P304

488-498

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2015.202

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan Ross Hart

John C. Burnett

P577

2015-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284185349

http://www.w3.org/2001/XMLSchema#string

P698

26581162

http://www.w3.org/2001/XMLSchema#string

P921

P932

4786915

http://www.w3.org/2001/XMLSchema#string